Trials / Terminated
TerminatedNCT04708834
Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder
A Multicenter, Long-Term Open-Label Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 772 (actual)
- Sponsor
- Biohaven Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compulsive disorder (OCD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Troriluzole (BHV-4157) | 200 mg daily first 2 weeks, 280 daily following first 2 weeks |
Timeline
- Start date
- 2021-03-30
- Primary completion
- 2026-02-13
- Completion
- 2026-02-13
- First posted
- 2021-01-14
- Last updated
- 2026-02-25
Locations
175 sites across 6 countries: United States, Canada, Italy, Netherlands, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04708834. Inclusion in this directory is not an endorsement.